Global rivastigmine transdermal patches market was valued at $882.5 million in 2025 and is expected to reach $1,869.9 million by 2035, expanding at a CAGR of 7.9% over the forecast period from 2026 to 2035. The expanding burden of neurodegenerative diseases, led by Alzheimer’s disease, represents a key demand driver for the market. It directly enlarges the long-term treated population requiring cholinesterase inhibitor therapy. CDC estimates 6.7 million older adults in the US live with Alzheimer’s disease and projects this figure will rise to nearly 14 million by 2060, indicating a sustained expansion in diagnosis and ongoing management needs over the forecast horizon. The same public health data environment also indicates disease severity, with CDC reporting 114,034 deaths from Alzheimer’s disease in 2023, reinforcing the scale of clinical engagement and continuous therapy support across mild-to-advanced stages. This growing patient base is material for market estimation because it supports higher initiation rates, longer treatment duration, and dose optimization across commonly used patch strengths in routine care.
Browse the full report description of “Rivastigmine Transdermal Patches Market Size, Share & Trends Analysis Report, By Type (4.6mg/24hr, 9.5mg/24hr, and 13.3 mg/24hr), By Application (Alzheimer’s Disease, Parkinson’s Disease, and Others), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/rivastigmine-transdermal-patches-market
Transdermal delivery strengthens this demand cycle by aligning with real-world treatment requirements in cognitively impaired populations, where consistent administration, caregiver convenience, and tolerability can influence persistence. NIH’s National Institute on Aging reported in 2025 that an estimated 7.1 million Americans are currently living with symptoms of Alzheimer’s disease, with projections reaching 13.9 million by 2060, supporting continued growth in the addressable population for maintenance therapies. Parkinson's-related demand also contributes, as the National Institute of Neurological Disorders and Stroke notes that the number of people diagnosed with Parkinson’s disease in the United States is expected to double by 2040, expanding the longer-term patient pool in which cognitive impairment becomes a significant clinical priority. Together, these government-reported trends reinforce steady uptake of rivastigmine patches across hospital initiation pathways and ongoing outpatient management, while also supporting recurring demand for patch-based regimens in Alzheimer’s disease, Parkinson’s disease dementia, and related indications.
Key Innovators Advancing the Rivastigmine Transdermal Patches Market
The key players in the rivastigmine transdermal patches market include Novartis AG, Teva Pharmaceutical Industries Ltd., Viatris Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., among others. These companies are driving innovation in rivastigmine transdermal patch technologies through improved drug-delivery formulations, enhanced skin adhesion and tolerability, and optimized dosing profiles, supporting long-term therapy adherence and effective management of neurodegenerative disorders across global healthcare markets.
Market Coverage
Key questions addressed by the report.
Global Rivastigmine Transdermal Patches Market Report Segment
By Type
By Application
Global Rivastigmine Transdermal Patches Market Report Segment by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/rivastigmine-transdermal-patches-market